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ABSTRACT: Background: Oesophageal cancer (OC) is a deadly cancer because of its aggressive nature with 
survival rates that have barely improved in decades. Epidemiologic studies have shown that low-dose daily intake 
of aspirin can decrease the incidence of OC.  
Methods: The toxicity of aspirin and aspirin derivatives to OC and a CRC cell line were investigated in the 
presence and absence of platins.  
Results: The data in this study show the effects of a number of aspirin analogues and aspirin on OC cell lines that 
originally presented as squamous cell carcinoma (SSC) and adenocarcinoma (ADC). The aspirin analogues 
fumaryldiaspirin (PN517) and the benzoylsalicylates (PN524, PN528 and PN529), were observed to be more toxic 
against the OC cell lines than aspirin. Both quantitative and qualitative apoptosis experiments reveal that these 
compounds largely induce apoptosis, although some necrosis was evident with PN528 and PN529. Failure to 
recover following the treatment with these analogues emphasized that these drugs are largely cytotoxic in nature. 
The OE21 (SSC) and OE33 (ADC) cell lines were more sensitive to the aspirin analogues compared to the Flo-1 
cell line (ADC). A non-cancerous oesophageal primary cells NOK2101, was used to determine the specificity of 
the aspirin analogues and cytotoxicity assays revealed that analogues PN528 and PN529 were selectively toxic to 
cancer cell lines, whereas PN508, PN517 and PN524 also induced cell death in NOK2101. In combination index 
testing synergistic interactions of the most promising compounds, including aspirin, with cisplatin, oxaliplatin and 
carboplatin against the OE33 cell line and the SW480 colorectal cancer (CRC) cell line were investigated.  
Compounds PN517 and PN524, and to a lesser extent PN528, synergised with cisplatin against OE33 cells. 
Cisplatin and oxaliplatin synergised with aspirin and PN517 when tested against the SW480 cell line.  
Conclusion: These findings indicate the potential and limitations of aspirin and aspirin analogues as 
chemotherapeutic agents against OC and CRC when combined with platins.    
  
1. INTRODUCTION 
]Worldwide, oesophageal cancer (OC) is estimated to be the 7th most commonly diagnosed cancer, with over 
570,000 developing the disease and approximately 500,000 deaths predicted to occur in 2018 [1]. A significant 
proportion of patients present with advanced or metastatic disease upon diagnosis [2]. More than half of OC 
diagnosed is an adenocarcinoma (ADC), originating from the distal third of the oesophagus and is associated with 
gastric reflux and Barrett’s oesophagus (BO), where columnar epithelium replaces the normal squamous 
epithelium [3]. By contrast, squamous cell carcinoma (SCC) largely arises above the tracheal bifurcation and is 
responsible for more than a quarter of cases of OC [4]. Given that OC overall has a dismal 5-year survival rate of 
19.2% (USA: https://seer.cancer.gov/statfacts/html/esoph.html) and with survival rates barely improving in over 
a generation, there is a need to identify novel chemotherapeutic agents that have the potential to target this cancer 
and/or can synergise with current treatment modalities. This need is underscored by the finding that the incidence 
of oesophageal adenocarcinoma appears to be on the rise [5]. 
 Several studies have reported that regular intake of aspirin (acetylsalicylic acid) or non-steroidal anti-
inflammatory drugs (NSAID) can result in reduced morbidity or mortality from gastrointestinal cancer. For 
example, Thun et al. suggested that death rates decreased with aspirin usage for colorectal, stomach and 
oesophageal cancer in comparison to other cancers [6].  Funkhouser and Sharp, and Farrow et al. found that aspirin 
users were at a significantly decreased risk from OC [7, 8]. In addition, in a meta-analysis study based on exposure 
type, aspirin usage was found to have greater protective effect than non-aspirin NSAIDs against the development 
of OC [9], but any use was protective against both histological types (ADC: OR=0.67 and SCC: OR=0.58]. Two 
more recent meta-analyses lend credence to the protective nature of regular aspirin use: Bosetti et al. estimates a 
statistically significant reduced relative risk of 0.64 for squamous cell oesophageal cancer [10], and Cuzick et al. 
report a best estimate risk ratio of 0.7 for incidence and 0.5 for mortality for OC [11]. Barrett’s oesophagus patients 
also using NSAIDs exhibit a significantly reduced risk of developing oesophageal ADC (6.6%) compared to non-
users (14.3%) [12]. 
 It has been suggested that the reduced cancer risk in BO patients using NSAIDs could be a consequence 
of a decreased rate of acquisition of somatic genomic abnormalities [13], an intriguing finding given that 
inflammation and genetic instability is intimately linked (e.g. see [14]. NSAIDs can also prevent OC 
experimentally; for example, indomethacin reduced diethylnitrosamine induced OC in mice [15] and  
ursodeoxycholic acid in combination with aspirin reduced the risk of oesophageal ADC in a rat model of BO [16]. 
Studies suggest that aspirin (and indeed other NSAIDs) exert their anti-cancer effects through cyclooxygenase 
(COX)-dependent and COX-independent pathways [17-20]. Aspirin inhibits PG production by the irreversible 
acetylation and inhibition of the cyclooxygenase activity in PGHS [21]. Overexpression of COX-2 in tissues has 
been intimately linked with cancer progression [22]. Prostaglandin E2 (PGE2), a major prostanoid produced by 
COX-2, promotes cell proliferation, metastasis, angiogenesis and resistance to apoptosis [23]. Increased COX-2 
expression is seen in BO and human oesophageal cancer (SCC and ADC) [24-27]. The evidence for a role of 
COX1 in the pathophysiology of cancer is weaker [28, 29]. 
 The evidence supporting COX-independent targets for aspirin (and the metabolite salicylate) is 
increasing, and include (but are not limited to) the NF-kB pathway [30, 31] which is critically important in 
inflammatory responses, activation of the p38 MAP kinase pathway with subsequent cyclin D1 degradation [32], 
down-regulation of Bcl-2 expression [33] and mTOR inhibition and activation of AMP-activated protein kinase 
[34, 35].  Aspirin usage after a diagnosis of colon cancer also has a positive outcome: longer survival is noted 
among patients with mutated-PIK3CA colorectal cancer, but not with wild type PIK3CA cancer [36]. Taken 
together, these observations suggest that aspirin can act pleiotropically. We have identified aspirin analogues that 
are more potent than aspirin with respect to inhibition of colorectal cancer cell line growth in vitro and in vivo, 
have the capacity to induce apoptosis, inhibit NF-kB and reduce cyclin D1 levels [37, 38]. Herein, we have 
extended our investigation into aspirin analogues (Table 1) and examined their cytotoxicity to the OC cell lines 
OE21, OE33 and Flo-1, given the evidence that aspirin may be chemoprotective against OC. 
2. MATERIALS and METHODS 
2.1 Chemicals and reagents. Dulbecco's modified Eagle's medium (DMEM), RPMI-1640 medium, foetal bovine 
serum (FBS), L-glutamine and antibiotic solution were from Life Technologies Ltd or Gibco (Paisley, UK). 
Epithelial cell medium (EpiCM) kit was from ScienCell research laboratories (Carlsbad, CA, USA). The Annexin-
V-Fluos staining kit for flow cytometry was from Roche Diagnostics Operations Inc. (Indianapolis, USA). 
Carboplatin, oxaliplatin and cisplatin (cis-diamminedichloroplatinum (II)) were from Stratech Scientific Ltd., 
Newmarket, UK. Dimethyl sulphoxide (DMSO), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT), and all other reagents, unless otherwise specified were obtained from Sigma-Aldrich Company Ltd 
(Dorset, UK).  
 
2.2 Compound synthesis. 
Preparation of PN510. This was prepared in an analogous way to PN508 [37] using adipoyl chloride in lieu of 
succinyl chloride. The off-white solid had a melting range of 174 -176oC [lit.,171-174oC [39]]. 
Preparation of PN526 and PN527. These carbonate esters were prepared by a variation of the general method for 
synthesis of alkanoylsalicylate analogues according to Deb et al. [37],  but using methyl chloroformate and 
ethylchloroformate, instead of an acid chloride, respectively. As an example, PN527 was synthesized by placing 
salicylic acid (6.9 g; 0.05 mol) to a 250 ml round bottomed flask fitted with a clamp, condenser, a small dropping 
funnel and magnetic stirrer. Diethyl ether (dried over anhydrous magnesium sulphate, 24 h, 100 ml) was added 
and stirred until the salicylic had completely dissolved, at which point pyridine (4 ml; 0.05 mol) was added. The 
apparatus was fitted with calcium chloride guard tubes, throughout, to exclude moisture. Ethyl chloroformate 
(5.47 ml; 0.05 mol) was added through the dropping funnel (drop wise) over a period of 10 min. The mixture was 
then vigorously stirred for a further 30 min, after which a precipitate of pyridinium chloride was clearly visible. 
A further 50 ml dry diethyl ether was added and the solution was stirred for 10 min. The solution was filtered into 
a 500 ml conical flask and deionized water (100 ml) was added.  The solution was vigorously stirred for 5 min 
before the ether layer was separated, dried over anhydrous magnesium sulphate and rotary-evaporated to dryness. 
The crude product (9.1 g; 93%) was an oil that soon crystallised. The product was dissolved in hot toluene (25-30 
ml), cooled and stored at -15°C for 1 week to give a colourless solid: (yield 7.20 g); IR: ν C=O acid 1682/cm-1, ν 
C=O ester (1) 1756/cm-1, ν C=O ester (2) 1756/cm-1; mp: 96-98˚C (lit., not found).  
 For PN526; crude yield = 79% recrystallised from ethanol in a similar manner to that described 
above; IR: ν C=O acid 1682/cm-1, ν C=O ester (1) 1757/cm-1, ν C=O ester (2)1757/cm-1; mp: 140-142˚C (lit. 
134˚C, U.S. Environmental Protection Agency: 
https://comptox.epa.gov/dashboard/dsstoxdb/results?search=Carbonic+acid,+methyl+ester,+ester+with+salicyli
c+acid). 
2.3 Compound preparation. Aspirin and aspirin analogues were prepared as fresh stock solutions in DMSO, 
usually at a concentration of 0.25 M, before each experiment.  
 
2.4 Cell culture. The human oesophageal cancer cell lines and primary oral keratinocyte NOK2101cell line were 
obtained from Mr Tim Underwood (University of Southampton). The OC cell lines OE21 (of SCC origin)  and 
OE33 (of ADC origin) [40] were cultured in RPMI-1640 medium with L-glutamine supplemented with 10% (v/v) 
heat inactivated FBS and penicillin-streptomycin. The Flo-1 OC cell line (of ADC origin) [41] was cultured in 
DMEM medium with L-glutamine supplemented with 10% heat inactivated FBS and penicillin-streptomycin 
solution. The primary keratinocyte cells, NOK2101 were maintained in EpiCM medium supplemented with 10% 
FBS and penicillin-streptomycin solution. The SW480 colon adenocarcinoma cell line (ECACC, Salisbury, UK) 
was cultured in Leibovitz L-15 medium (Thermo Fisher Scientific) containing 10% (v/v) FBS supplemented with 
L-glutamine-penicillin-streptomycin in sealed culture flasks. The cells were cultured at 37ºC in a humidified 
incubator with 5% CO2 and regularly passaged at ~80% confluency. 
 
2.5 Anti-proliferative potency of compounds. The cytotoxic effect of aspirin analogues on the oesophageal cancer 
cells and the non-cancerous keratinocyte cell line was tested using the MTT assay [42]. Briefly, 2.5 ×103 (OE21 
cells) or 104 cells/well were seeded in 96-well microtitre plate and cultured overnight. After 24 h of initial seeding, 
the culture medium was replaced with fresh medium containing drugs or vehicle control and incubated at 37ºC. 
On completion of incubation, the supernatant was aspirated and cells incubated with 300 μl of MTT substrate (0.5 
mg/ml) for 3 h. The supernatant was removed and the resultant formazan crystals were dissolved in 200 μl of 
DMSO. The absorbance was read at 540 nm using a microplate reader (Microplate Reader Thermo Multiskan 
Ascent 96 & 384). Metabolic activity (viability) is reported as the percentage of treated cells relative to the 
untreated cells in control wells.  Both readings were background subtracted, using the absorbance at time zero. 
Growth inhibition values (IC50) were determined using a non-linear sigmoidal plot with 4 variable parameters 
(Minimum, maximum, IC50 value and Hill slope were not fixed). pIC50 (-logIC50), minimum, maximum and Hill 
slopes were treated as being normally distributed, allowing parametric analyses to be performed. All data analysis 
was performed using GraphPad Prism Statistics Software package (ver. 6.0; San Diego, CA, USA). 
2.6 Apoptosis with Annexin-V-fluos staining and flow cytometry analyses. The ability of aspirin analogues to 
induce apoptosis was tested in vitro using a commercially available Annexin-V-Fluos cell staining kit. Briefly, 
cells were cultured in 25 cm2 flask until they reached ~50% confluency. Cells were incubated for the indicated 
time with compounds (1 mM). Following incubation, cells were harvested and washed in Hank’s balanced salt 
solution (HBSS) buffer and incubated with labelling solution (100 μl incubation buffer with 2 μl Annexin-V-
Fluos reagent and 2 μl of propidium iodide (PI) used for ~106 cells) for 10-15 min at room temperature as per the 
manufacturer’s instructions. Cells were further diluted, if required, with HBSS buffer and analysed on a flow 
cytometer (BD Biosciences, Facscalibur). A positive control for apoptosis (irinotecan, 25 μM), positive control 
for necrosis (H2O2, 2 mM) and untreated control cells were included in the experiment for comparison. Flow 
cytometry settings used were excitation wavelength of 488 nm and bandpass filter of 530 nm for fluorescein 
(green) detection and for PI, a bandpass filter of 600 nm was employed. Use of the PI counter-stain with the 
principal stain enabled discrimination of viable cells from non-viable cells and apoptotic cells from necrotic cells.  
Viable cells do not take up either stain whereas non-viable cells take up only PI. Apoptotic cells take up the 
Annexin-V/ApoTRACE stain but not PI whereas necrotic/late apoptotic cells take up both principal and PI stain.  
For detection of early apoptosis and late apoptosis/necrosis, cells were gated into three populations: Annexin-/PI- 
(viable), Annexin+/PI- (early apoptotic), and Annexin+/PI+ (late apoptotic/necrotic). 
 
2.7 Evaluation of cytotoxicity and cytostaticity of compounds. OE21, OE33 and Flo-1 cells were seeded at a 
density of 5×103, 2×104 and, 2×104 cells/well respectively, in 96-well plates in their respective basal medium. 
After 24 h seeding, the cells were treated with compound-containing culture medium for a further 72 h; cells were 
treated with either aspirin compounds (1 mM), irinotecan (25 μM), H2O2 (2 mM) or vehicle control. The 
supernatant was removed and adherent cells were harvested and washed with phosphate buffered saline. Cells 
were then reseeded, at the same density as the initial seeding, in a fresh plate with drug-free medium and allowed 
to recover for 72 h at 37ºC. Following this recovery period, cells were collected by trypsinization and counted 
using a Beckman Coulter Z1 cell counter with an orifice of 100 µm and threshold size of 10 µm.  
 
2.8 Synergy with conventional anticancer drugs. OE33 cells were plated in a 96-well plate at a density of 1.0 X 
104 cells/well and incubated overnight at 37°C. The cells were then treated with serially diluted concentrations of 
cisplatin, oxaliplatin, carboplatin, aspirin and its analogues for 72 h [43-47]. Cell viability was measured by MTT 
assay and the IC50 was calculated for each compound. Combination drug treatments were then performed as above 
by pairing cisplatin, oxaliplatin or carboplatin with each of the aspirin analogues in a constant ratio design based 
on the IC50. All assays were performed in duplicates (N=3). CompuSyn software ver. 1.0 published and distributed 
by ComboSyn Inc., (Paramus, NJ., USA) was used to calculate the Combination Index (CI) and Dose Reduction 
Index (DRI). This produces multiple drug dose-effect calculations using the Median Effect methods described by 
Chou and Talalay [48]. The CI is the quantitative measure of the degree of drug interaction in terms of additive 
effect (CI = 1), synergism (CI < 1), or antagonism (CI > 1) while the DRI is the measure of favourable dose 
reduction when two drugs are used in combination. Graphpad Prism 7 software (ver. 7.0a, April 2016) was used 
to calculate the IC50 of individual compounds and their respective combinations. A description and interpretation 
of synergism or antagonism in combination studies using the CI method of analysis [adapted from [49, 50]] is 
presented (Table 2). 
 
3. RESULTS 
3.1 Aspirin analogues show anti-proliferative activity against oesophageal cancer cells.  
Using the MTT cell viability assay a number of aspirin analogues including ‘diaspirins’: PN508, PN510, PN511, 
PN512 and PN517; ‘benzoylsalicylates’: PN514, PN524, PN525, PN528 and PN529; and ‘carbonates’, PN526 
and PN527, were screened for their efficacy to kill oesophageal cancer cells (Figure 1). Aspirin and salicylic acid 
(SA) were included in the experiment as controls. Assay results demonstrated that the benzoylsalicylates; PN524, 
PN528 and PN529 to be substantially more potent in killing OE21 and OE33 cells than PN508 and aspirin itself 
(Figures 1A, 1B). PN517 was not as effective as the benzoylsalicylates, exhibiting modest cytotoxicity to these 
cells. Conversely, the Flo-1 cell line was resistant to most of the compounds tested other than PN528 and PN529 
(Figure 1C). PN514 was more potent in killing OE21 cells, whereas PN512 was more cytotoxic to OE33 cells. 
Other compounds including PN510, PN511, PN525, PN526 and PN527 failed to show robust cytotoxicity towards 
the three cancer cell lines (Figure 1) and were not investigated further. MTT analysis of aspirin analogues on the 
non-cancerous primary cell type NOK2101 showed a rather complex and differential response compared to cancer 
cells. Aspirin and SA showed little or no killing of NOK2101 cells at the concentration tested. The differential 
toxicities of PN528 and PN529 is noteworthy. They were most effective against the oesophageal adenocarcinoma 
OE33 and Flo-1, causing over 75% reduction in the MTT assay. In contrast, they only reduced NOK2101 
proliferation by under 35% and of the analogues, PN512 and PN514 showed the least cytotoxicity to the NOK2101 
cells.   
 Using MTT data, dose response curves were determined and IC50 values were calculated for each of the 
aspirin analogues (Table 1). The compounds were found to suppress the proliferation of OC cells in a dose-
dependent manner (data not shown). PN529 was the most cytotoxic compound, with IC50 values in the range of 
100-400 µM. In comparison, aspirin ranged between 1 mM and 7 mM. Determination of the IC50 values indicates 
OE21 cells are more sensitive to these compounds.  
3.2 Aspirin analogue-mediated cancer cell killing is through induction of apoptosis. To examine whether 
treatment with aspirin analogues resulted in cell death through apoptosis or necrosis, treated cells were stained 
and subsequently imaged using fluorescence microscopy. Controls for apoptosis (irinotecan) and necrosis (H2O2) 
were also used. The quantitative assay utilized staining of apoptotic cells with Annexin-V, which shows affinity 
to phosphatidylserine on the cell surface, with analysis using flow cytometry [51]. Following 48 h treatments, 
analysis suggests that most of the analogues exert their toxicity through the induction of apoptosis (Figure 2). 
However, some necrosis was observed upon incubation with PN528 and PN529 (data not shown). Flow cytometric 
analysis at 72 h revealed PN524 and PN517 to be the leading analogues inducing apoptosis in OE21 and OE33 
cells; in contrast PN528 and PN529 were found to induce more apoptosis in Flo-1 cells (Figure 2). 
3.3 Aspirin analogues are cytotoxic in nature. A cell recovery assay was performed to examine whether treatment 
with aspirin and aspirin analogues induced cytostasis or cell death. In general, treatment with irinotecan or H2O2 
was detrimental to the cancer cells at the concentrations tested with cells failing to recover during the recovery 
period. OE21 cells failed to thrive following treatment with compounds (Figure 3). In contrast OE33 cells treated 
with aspirin appear to grow more rapidly upon its removal. This trend may also be present in Flo-1 cells. In 
contrast, PN528 and PN529 showed cytotoxic effects towards all OC cells tested. PN517 and PN524 appeared to 
be more cytotoxic to OE21 cells and cytostatic towards Flo-1 cells. 
3.4 Combination index testing of platins and salicylates in OE33 and SW480 cancer cells. We aimed to establish 
what effect combining aspirin and aspirin analogues with platins would have against the OE33 (chosen given the 
intermediary nature of these cells’ responses to compounds) and the SW480 colorectal cancer cell line. Identifying 
a means to decrease the dose needed for these platinum compounds is of importance in clinical care because of 
their narrow therapeutic index [52]. Given the findings reported herein regarding toxicity, specificity and apoptotic 
and necrotic potential, we investigated the capacity of platins to synergise with selected compounds including 
aspirin (PN502), PN517, PN524 and PN528. 
 Cisplatin in combination with aspirin [1:100 ratio] at the ED50 against the OE33 oesophageal cancer cells 
had an antagonistic effect. Synergistic effects were observed however, when cisplatin was combined with PN517 
[1:50] with the ED50 for cisplatin reduced from 5.4 μM to 1.5 μM. Synergistic effects at ED50, ED75 and ED90 
were also observed when cisplatin was combined with PN524 [1:50] against the oesophageal cell line and was 
accompanied by a reduction in the ED50 of cisplatin from 5.4 μM to 2.3 μM. The ED50 for cisplatin when used in 
combination with PN517 [1:50] was reduced from 5.4 μM to 1.5 μM while that of PN517 was reduced from 600 
μM to 75 μM. The ED50 was reduced from 5.4 μM and 408 μM to 2.3 μM and 113 μM respectively for cisplatin 
and PN524 [1:50] in combination. The cisplatin and PN528 combination resulted in a decrease in ED50 for 
cisplatin from 5.4 μM to 3.5 μM. Oxaliplatin in combination with aspirin [1:20] had synergistic effects at ED50 
and below, which indicates synergy at low doses with little cytotoxic effects, but this is not relevant in cancer 
therapy. Oxaliplatin in combination with PN517 and PN524 against the OE33 oesophageal cancer cell line had 
antagonistic effects at ED75 and ED90 with synergy at ED50 and below. Antagonistic effects were also observed 
when carboplatin was used in combination with aspirin and PN517, but in combination with PN524 [1:20], 
however, had a synergistic effect at ED50 and below with combinations having antagonistic effects at ED75, and 
ED90. The ED50 of carboplatin when combined with PN524 was reduced from 40.8 μM to 11.7 μM, which is an 
approximately 4-fold reduction in dose to kill 50% of the oesophageal cancer cells. PN524 in combination with 
oxaliplatin and carboplatin had synergistic effects at ED50 and lower.  Antagonism was noted when oxalipatin and 
carboplatin were tested in combination with PN528, although slight/moderate synergy was observed with cisplatin 
at ED75 and ED90 respectively.  
 In contrast, in the SW480 CRC cell line, synergy/strong synergy was observed when aspirin was 
combined with cisplatin and oxaliplatin. Moreover, synergy was observed when cisplatin was combined with 
PN517 [1:10] with a 5-fold decrease in the ED50 for cisplatin. Remarkably, the ED50 for oxaliplatin had a 7-fold 
decrease when combined with PN517 resulting in a strong synergistic effect which was also apparent at ED75 and 
ED90. Cisplatin in combination with PN524 [1:40] had synergistic effects with about a 7-fold decrease in ED50 for 
cisplatin. The synergistic effects of these combinations increased at higher dose, which is advantageous in 
chemotherapy (data not shown). However, although there was a synergistic effect when oxaliplatin was combined 
with PN524 [1:8] at ED50, the effect regressed to antagonism with increased dose (ED75 and ED90), a result that is 
not likely to produce the maximum cytotoxicity required in cancer therapy [53]. Moreover, the dose of carboplatin 
at ED50 increased rather than decreased when used in combination with the aspirin analogue PN524 (101 μM 
alone to 152 μM in combination); this increase in ED50 of defeats one of the main reasons of combination therapy, 
which is to achieve a decrease in effective dose in order to reduce or alleviate side effects. Some of the 
combinations showed strong antagonism due to very high CI values; this is possible in some combinations as the 
synergy scale is from 1 to 0 and the antagonism scale is from 1 to infinity [53].  The differences in outcomes for 
each drug combination in different cell lines may be due to differences in target specificity of the compounds [54].  
 For clarity, a summary of the effects of all the combinations as determined by their CI values against 
OE33 oesophageal and SW480 colorectal cancer cell lines calculated utilising CompuSyn can be found in Table 
3. 
 
4.  DISCUSSION 
Given the evidence that aspirin may be chemoprotective against OC, we have investigated the cytotoxicity of 
aspirin analogues to the OC cell lines OE21, OE33 and Flo-1. The aspirin analogues fumaryldiaspirin (PN517) 
and the benzoylsalicylates (PN524, PN528 and PN529), were observed to be more toxic against the OC cell lines 
than aspirin. Of note are PN528 and PN529, which were particularly effective against oesophageal 
adenocarcinoma cell lines, OE33 and Flo-1, while showing reduced toxicity towards non-cancerous NOK2101 
cells. These compounds appear to act by inducing apoptosis.  Some necrosis, albeit not statistically significant in 
our studies was evident with PN528 and PN529. This should not be attributed to late apoptosis as the same was 
not observed when irinotecan was used.  
 We obtained surprising results when looking at the ability of cells to recover following removal of the 
drugs.  The “rebound effect” is well understood with aspirin when looking at cardiovascular effects [55]. An 
increase of cardiovascular events by 30% can be observed if low-dose aspirin is stopped. We are unaware of data 
looking at the incidence of cancer following such removal of treatment. Our observations with aspirin suggest 
tumours may grow more vigorously should treatment be halted.  In contrast removal of PN528 and PN529 in 
particular showed they were largely cytotoxic and did not permit any rebound growth. The OE21 (SSC) and OE33 
(ADC) cell lines were more sensitive to the aspirin analogues compared to the Flo-1 cell line (ADC). Utilising a 
non-cancerous oesophageal primary cell line NOK2101 revealed that analogues PN528 and PN529 had some 
selective toxicity to cancer cell lines, whereas PN508, PN517 and PN524 also induced cell death in NOK2101. 
  This issue of lack of specificity spurred us on to investigate whether synergistic action with platins 
commonly used in cancer treatment with the aspirin analogues and with aspirin itself was possible. In the OE33 
oesophageal cancer cell line, none of the platinum compounds synergised with aspirin. Although there was 
synergy when oxaliplatin and aspirin were combined at ED50, this effect regressed at ED75 and ED90 and thus is 
not favourable in the treatment of cancer. In gastric cancer cells however, cell growth was significantly inhibited 
when cisplatin was used in combination with aspirin [56]. In our studies, the combination of cisplatin and PN517 
maintained its synergistic effects through ED50, ED75 and ED90, which make this a promising combination for the 
treatment of oesophageal cancer, as a synergistic effect between these two compounds is maintained at different 
dose effects. In contrast, oxaliplatin and carboplatin in combination with PN517 largely exhibited antagonistic 
effects; although there was moderate synergy between oxaliplatin and PN517 at ED50, the positive effect decreased 
as doses increased (at ED75 and ED90), which is not favourable in the treatment of cancer because maximum 
cytotoxicity against the cancer cells is critical to effective therapy [53].  Cisplatin and PN524 exhibited synergy 
at ED50, ED75 and ED90. Although oxaliplatin and carboplatin showed synergistic effects with PN524 at ED50, the 
effects declined at ED75 and ED90 respectively. Slight synergy was observed when cisplatin was tested in 
combination with PN528. 
 In the SW480 CRC cell line substantive synergy was observed when aspirin (PN502) and PN517 were 
combined with cisplatin and oxaliplatin with a decrease in ED50 for these platinum compounds. Surprisingly, 
antagonistic effects were observed when aspirin was used in combination with carboplatin. PN524 synergised 
with cisplatin. Given the common use of oxaliplatin in the treatment of colorectal cancer and with a clinically 
significant side effect of oxaliplatin being peripheral neuropathy [52], a reduction in its ED50 as a result of 
combination with aspirin and PN517 and PN524 may have clinical utility: a reduction in drug concentration will 
result in toxicity reduction and also delay or minimize the induction of drug resistance [53]. It is worth pointing 
out that whilst the concentration of the compounds tested in the experiments outlined may seem rather high in 
comparison to other chemotherapeutic agents, a range of 1-5 mM or above is not uncommon in in vitro and in 
vivo experiments investigating the molecular action of aspirin or salicylate [35, 54, 57, 58] 
CONCLUSION 
Notwithstanding the uncertainties regarding the precise molecular targets of aspirin and indeed, the aspirin 
analogues tested herein, we present evidence of synergistic potential with platinum compounds (particularly 
cisplatin) and suggest these findings should be extended to in vivo analyses in more clinically relevant models 
given the somewhat refractory nature of oesophageal and colorectal cancer. We find that the novel aspirin 
analogues were significantly more potent against oesophageal cancer cell lines than aspirin itself, and that the 
compounds can induce apoptosis. The inability of the cancer cells to recover following treatment with these 
analogues suggests that these drugs can be cytotoxic and not cytostatic in nature. The OE21 cell line (of SCC 
origin) was found to be the most sensitive cell line, whereas Flo-1 cells (ADC) were found to be more resistant. 
Perhaps most significantly, we also find that selected aspirin analogues can synergise with platins against the 
OE33 and SW480 cancer cell lines, and that aspirin can synergise with cisplatin and oxaliplatin against the SW480 
cell line. 
  
FIGURE LEGENDS 
Figure 1. Screening aspirin analogues for their potency towards oesophageal cancer cell lines and a non-cancerous 
keratinocyte cell line in vitro.  (A) OE21, (B) OE33, (C) Flo-1 and (D) NOK2101 cells were cultured for 24 h and 
the cells were then treated with compound-containing (1 mM) culture medium for 72 h. The anti-proliferative 
effects were then measured. Data are plotted as mean ± SEM (N=3). The effect of aspirin and salicylic acid (SA) 
is included for comparison. Two-tailed one-way ANOVA followed by Dunnett’s post hoc test (comparing data 
with aspirin) showed * p ≤ 0.05 and ** p ≤ 0.01, *** p ≤ 0.001. 
Figure 2.  Compound induced apoptosis in oesophageal cancer cell lines. Following 72 h treatment with 
compounds (1 mM), cells were stained with Annexin-V-Fluos and counter-stained with PI and the population of 
cells undergoing apoptosis was measured by FACS analysis. Irinotecan (IRI) and H2O2 were used as positive 
controls for apoptosis and necrosis, respectively. The effect of aspirin and DMSO (vehicle control) is included for 
comparison.  Data plotted as mean ± SEM (N=3).  Two-tailed one-way ANOVA followed by Dunnett’s post hoc 
test (comparing data against vehicle control) showed * p ≤ 0.05 and ** p ≤ 0.01.  
Figure 3. Recovery of oesophageal cancer cells following withdrawal of aspirin and aspirin compounds. OE21, 
OE33 and Flo-1 cells were treated with compound containing culture medium (1mM) for 72 h; viable/adherent 
cells were harvested, counted and re-seeded with compound-free-medium. After 72 h of recovery, cell counts 
were determined. The effect of aspirin, DMSO (vehicle control), irinotecan (IRI) and H2O2 is included for 
comparison. Data plotted as mean ± SEM (N=3, performed in duplicates). Two-tailed one-way ANOVA followed 
by Dunnett’s post hoc test (comparing data against vehicle control) showed * p ≤ 0.05 and ** p ≤ 0.01. 
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Common Name Chemical, formal name Laboratory 
number 
pIC50 ± SEM Notes, 
reference 
OE21 OE33 Flo-1 
Aspirin Acetylsalicylic acid PN502 2.90 ± 
0.04 
2.57 ± 
0.07 
2.16 ± 
0.02 
Commercially 
available 
Diaspirin 
(DiA) 
Bis(2-
carboxyphenyl)succinate, 
Succinylsalicylic acid 
PN508 3.07 ± 
0.01 
3.02 ± 
0.06* 
2.80 ± 
0.03* 
[37, 38] 
Adipoyldiaspirin Bis(2-
carboxyphenyl)adipate 
 
PN510 n.d. n.d. n.d. Synthesised in 
this study; [39] 
Sebacoyldiaspirin Bis(2-
carboxyphenyl)sebacate 
 
PN511 n.d. n.d. n.d. [38] 
 Bis(2-
carboxyphenyl)terephthalate 
PN512 3.07 ± 
0.04 
3.03 ± 
0.09* 
2.65 ± 
0.09* 
[38] 
 2-carboxyphenylbenzoate PN514 3.19 ± 
0.01* 
2.83 ± 
0.02 
2.4 ± 
0.1 
[37] 
Fumaryldiaspirin  
(F-DiA) 
Bis-carboxyphenylfumarate PN517 3.34 ± 
0.04* 
3.3 ± 
0.1* 
2.95 ± 
0.05* 
[38] 
 m-bromobenzoylsalicylate, 
2-carboxyphenyl 3’-
bromobenzoate 
PN524 3.62 ± 
0.10* 
3.17 ± 
0.06* 
3.05 ± 
0.07* 
[38] 
 p-methylbenzoylsalicylate, 
2-carboxyphenyl 4’-
methylbenzoate 
PN525 n.d. n.d. n.d. [38] 
 Methyl(2-
carboxyphenyl)carbonate 
2-carboxyphenyl methyl 
carbonate 
PN526 n.d. n.d. n.d. Synthesised in 
this study 
 Ethyl(2-
carboxyphenyl)carbonate 
2-carboxyphenyl ethyl 
carbonate 
PN527 n.d. n.d. n.d. Synthesised in 
this study 
Benzosalin 2-methoxycarbonylphenyl 
benzoate, 
methyl benzoylsalicylate 
PN528 3.64 ± 
0.05* 
2.80 ± 
0.07 
3.15 ± 
0.05* 
[38] 
 Isopropyl (m-
bromobenzoylsalicylate), 
2-(2-
propyloxycarbonyl)phenyl 
3’-bromobenzoate 
PN529 
3.99 ± 
0.04* 
3.4 ± 
0.1* 
3.62 ± 
0.03* 
[37, 38] 
   
 
Table 1. Aspirin and aspirin analogues examined in the study and their respective toxicity (represented as pIC50 
for selected compounds) towards the oesophageal cancer cell lines. pIC50 values were obtained by non-linear 
regression (GraphPad Prism 6). pIC50 is expressed as the mean ± SEM of the data from three independent 
experiments. * pIC50 values were significantly different to aspirin (PN502) control, corrected for multiple 
comparisons determined using 1-way ANOVA with Dunnett’s post hoc test, p<0.01. n.d. = not determined. 
 
  
 Table 2 Combination Index grading. 
 
Combination Index (CI) Graded Symbols Interpretation 
<0.1 +++++ Very strong synergism 
0.1-0.3 ++++ Strong synergism 
0.3-0.7 +++ Synergism 
0.7-0.85 ++ Moderate synergism 
0.85-0.9 + Slight synergism 
0.9-1.1  Nearly additive 
1.1-1.2 − Slight antagonism 
1.2-1.45 −− Moderate antagonism 
1.45-3.3 −−− Antagonism 
3.3-10 −−−− Strong antagonism 
>10 −−−−− Very strong antagonism 
Simplified CI values and their interpretation 
<0.8 Synergism 
0.8-1.2 Additive 
>1.2 Antagonism 
 
  
Table 3. Synergistic interaction with platins of aspirin and aspirin analogues to oesophageal and colorectal cancer 
cells 
 
Compounds Cisplatin (CDDP) Oxaliplatin (OX) Carboplatin (CB) 
CI values at 
ED50 ED75 ED90 ED50 ED75 ED90 ED50 ED75 ED90 
PN502 − −  +++ −− −−− −−− −−− − 
PN517 +++ +++ +++ ++ −−− −−−− −−− −−− −− 
PN524 +++ +++ +++ ++ −−− −−−− ++ −− −−− 
PN528 − + ++ −−− −−− −−− −−− −−− −−− 
 
Table 3A. Summary of drug combination CI values in OE33 oesophageal cancer cell line. Drug combinations 
with CI values at effective dose for 50% kill of the cell population (ED50), 75% of the population (ED75) and 90% 
of the population (ED90). Effect for each combination is synergistic [+], additive [] or antagonistic [−]. 
 
 
Compounds Cisplatin (CDDP) Oxaliplatin (OX) Carboplatin (CB) 
CI values at 
ED50 ED75 ED90 ED50 ED75 ED90 ED50 ED75 ED90 
PN502 +++ +++ ++ +++ +++ ++ −− −− −−− 
PN517 +++ ++++ ++++ ++++ ++++ +++ +++ + −−− 
PN524 + +++ +++ +++ −−− −−−−−  + +++ 
 
Table 3B. Summary of drug combination CI values in SW480 colorectal cancer cell line. Drug combinations with 
CI values at effective dose for 50% kill of the cell population (ED50), 75% of the population (ED75) and 90% of 
the population (ED90). Effect for each combination is synergistic [+], additive [] or antagonistic [−].  
  
   
   
 
